Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.

Recs

2
Player Avatar zzlangerhans (99.85) Submitted: 12/3/2012 6:32:58 PM : Outperform Start Price: $1.68 LXRX Score: +18.68

866M still seems like way to much cap for Lexicon, but it doesn't seem like much compared to the 1.5B cap the company briefly sported in August. Something is keeping the stock afloat and I can either play in the waves or resolutely hold a red thumb until the hot air finally escapes the balloon. I've seen hot air stocks like Opko and Star maintain disproportionate valuations for years, so I'll take a chance of getting swirled with a green thumb on Lexicon here. Phase III trials of telotristat in carcinoid syndrome and LX4211 in type II diabetes should keep some enthusiasm alive in 2013.

Featured Broker Partners


Advertisement